ImmunityBio (IBRX) Gross Margin (2023 - 2026)

ImmunityBio (IBRX) has 4 years of Gross Margin data on file, last reported at 99.46% in Q1 2026.

• Gross Margin for Q1 2026 came in at 99.46%, down 19.0% year-over-year; the trailing twelve-month figure through Mar 2026 was 99.34% (down 48.0% YoY), and the FY2025 annual result was 99.34%, down 66.0% from the prior year.
• Gross Margin was little changed at 99.46% in Q1 2026 per IBRX's latest filing, from 99.0% in the prior quarter.
• Over five years, Gross Margin peaked at 100.0% in Q2 2023 and troughed at 99.0% in Q4 2025.
• A 4-year average of 99.75% and a median of 100.0% in 2023 frame the typical range for Gross Margin.
• The sharpest annual moves came in 2024 and 2025: Gross Margin changed 0 bps in 2024, then tumbled 100 bps in 2025.
• A 4-year view of Gross Margin shows it stood at 100.0% in 2023, then changed by 0 bps to 100.0% in 2024, then retreated by 1 bps to 99.0% in 2025, then rose by 0 bps to 99.46% in 2026.
• Business Quant data shows IBRX's Gross Margin at 99.46% in Q1 2026, 99.0% in Q4 2025, and 99.45% in Q3 2025.